deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02836873

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Sponsor: Theracos

Conditions Type 2 Diabetes Mellitus
Interventions Bexagliflozin Placebo
Updated 17 times since 2017 Last updated: Jun 28, 2021 Started: Sep 23, 2016 Primary completion: Jan 11, 2018 Completion: Jan 11, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Theracos and has accumulated 17 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Jan 2018 · 6 months · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Jul 2019 · 6 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. May 2021 — Sep 2021 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Completed PHASE3

  2. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jul 2019 — Nov 2019 [monthly]

    Completed PHASE3

  4. Jan 2019 — Jul 2019 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2019 [monthly]

    Completed PHASE3

  6. May 2018 — Jun 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  7. Mar 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2018 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Theracos
Data source: Theracos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcalá de Henares, Spain , Alicante, Spain , Atsugi-shi, Japan , Auburn, United States , Austin, United States , Dijon, France , Fresno, United States , Hachioji-shi, Japan , Hollywood, United States , Kamakura-shi, Japan and 36 more locations